<DOC>
	<DOCNO>NCT02550327</DOCNO>
	<brief_summary>The objective study improve survival addition anakinra chemotherapy combination nab-paclitaxel , gemcitabine , cisplatin patient resectable potentially resectable pancreatic adenocarcinoma ( PDAC ) . The primary endpoint study determine whether combination abraxane , gemcitabine , cisplatin , anakinra improve disease-free survival ( DFS ) determine number patient meet surpass 11.5 month DFS . The secondary objective study evaluate effect anakinra combine three-drug regimen nab-paclitaxel , gemcitabine , cisplatin response rate overall survival diagnosis adverse event patient resectable potentially resectable PDAC . The investigator use benchmark 24 month overall survival ( OS ) determine many patient meet exceed goal . The investigator monitor , survey , patient ' health relate quality life treatment determine addition anakinra improve measure .</brief_summary>
	<brief_title>Gemcitabine , Nab-Paclitaxel , Cisplatin Anakinra Treatment Patients With Pancreatic Cancer</brief_title>
	<detailed_description>This single-arm , open-label pilot study . Patients receive Nab-paclitaxel , gemcitabine , cisplatin anakinra .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>A patient eligible inclusion study meet follow criterion : 1 . Male female ≥ 18 year age . 2 . Suspected PDAC prior diagnosis histological diagnosis adenocarcinoma pancreas confirm pathology . Mixed subtypes adenocarcinoma acceptable long majority cell ductal adenocarcinoma . Subjects suspect PDAC without biopsy pancreas mass appear metastatic disease . These subject enrol prior biopsy exclude diagnosis pancreas cancer confirm histology . 3 . American Joint Committee Cancer ( AJCC ) Stage IIII Pancreatic carcinoma . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 . 5 . Serum albumin ≥2.0 gm/dL . 6 . Expected survival ≥6 month . 7 . Adequate hematologic function define : Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Platelets ≥70,000/mm3 Hemoglobin &gt; 9 g/dL ( absence red blood transfusion ) . 8 . Adequate liver function , define : Serum total bilirubin ≤2 x ULN mg/dL , prior initiation treatment . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 x upper limit normal ( ULN ) . 9 . Adequate renal function , define serum creatinine ≤ 1.5 x ULN , creatinine clearance ≥50 mL/min 10 . All female child bear potential must agree use contraception avoid pregnancy throughout study one month last dose . 11 . Patients must accessible treatment followup . 12 . Patients must ability understand study , inherent risk , side effect potential benefit able give write informed consent participate . Patients may consent medical power attorney . A patient ineligible inclusion study meet follow criterion : 1 . &lt; 18 year age . 2 . History organ transplant . 3 . Other malignancy within five year , unless probability recurrence prior malignancy &lt; 5 % determine Principal Investigator base available information . 4 . Current , active immunosuppressive therapy cyclosporine , tacrolimus 5 . Significant uncontrolled congestive heart failure ( CHF ) , myocardial infarction significant ventricular arrhythmia within last 6 month . 6 . Active infection antibiotic within 48 hour prior study enrollment , include unexplained fever ( temp &gt; 38°C ) . 7 . Other severe and/or uncontrolled medical condition condition opinion investigator could affect participation patient study . 8 . Study consent form sign . 9 . Pregnant nursing woman . 10 . Known HIV positive status .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>resectable</keyword>
	<keyword>potentially resectable</keyword>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>PDAC</keyword>
</DOC>